Introduction
============

Breast cancer is one of the most common epithelial tumors and has been a major source of mortality among women. Many studies have shown that exposure to estrogen is an important induction factor for breast cancer. Blocking estrogen action represents an effective approach for breast cancer treatment. However, estrogen plays key roles in maintaining normal functions of the human body, such as reproductive, skeletal, cardiovascular and nervous system functions, by binding with estrogen receptors. Therefore, simply blocking estrogen action could adversely affect the body; therefore, selective estrogen receptor modulators are required.

Estrogen receptors belong to the nuclear receptor superfamily. They can be activated by estrogen, and in response, estrogen receptors bind to DNA and regulate the expression of target genes. To date, two forms of estrogen receptors, ERα and ERβ, have been identified. In spite of their significant sequence homology, there are notable differences in distribution and function of these receptors: ERα is predominantly expressed in bone, breast, prostate (stroma), uterus, ovary (thecal cells) and brain, whereas ERβ is usually present in ovary (granulose cells), bladder, colon, immune, cardiovascular and nervous systems^[@bib1],[@bib2],[@bib3],[@bib4]^.

ERα is responsible for the classic function of estrogen, and its antagonists could have anti-proliferative effects through the inhibition of estrogen binding. Meanwhile, activating ERβ may have anti-proliferative effects and therefore oppose the actions of ERα in reproductive tissue^[@bib5]^. Thus, ERβ is a potent tumor suppressor and plays a crucial role in many cancer types^[@bib6]^. Selective ERβ ligands are able to suppress breast cancer cell proliferation without stimulating the uterus. In addition, it has been reported that ERβ might be related to diabetes and inflammation^[@bib7],[@bib8],[@bib9]^. Existing data also suggest that selective activation of ERβ may treat Alzheimer\'s disease^[@bib10]^. However, these two subtypes of estrogen receptors are almost identical, and only two residues differ in the ligand binding pockets (LBP). Therefore, we are faced with a certain challenge in obtaining subtype-selective ligands. To date, some ERβ-selective scaffolds, such as geinstein and DPN, have been discovered^[@bib1],[@bib11]^. These nonsteroidal ligands are not only important probes to explore the biological effects of ERβ, but some of them also show potential for therapy^[@bib12],[@bib13]^.

Structure-based virtual screening is an effective method for finding bioactive ligands with a novel scaffold. In fact, virtual screening was applied in the search of ER ligands in our previous work^[@bib14]^. However, this method is time-consuming and focuses on the fitness between ligands and the protein. Considering those known selective ERβ ligands, ligand-based method such as pharmacophore modeling might provide additional information for subtype selectivity. A pharmacophore model is a hypothesis of molecular features necessary for the bioactivity of a ligand. Typical pharmacophore features usually include hydrophobes, hydrogen bond acceptors or donors, aromatic rings, cations or anions. Based on these chemical features, some hit compounds retrieved by pharmacophore screening are similar to known active ligands, while some others are novel scaffolds. Therefore, pharmacophore screening is not only a valuable tool for scaffold hopping, but is also time-saving. In our previous work, subtype-specific pharmacophore models were developed for both ERα and ERβ, which were capable of capturing selective ligands^[@bib15]^.

In this study, a strategy combining pharmacophore and structure-based virtual screening was performed to discover novel ERβ selective ligands from two commercial databases ([Figure 1](#fig1){ref-type="fig"}). Maybridge and Enamine databases were first screened by our pharmacophore model of ERβ selectivity, and then molecular docking was conducted in the second filtering. Finally, 95 selected compounds were purchased and tested using a yeast two-hybrid (Y2H) assay. Among the tested hits, 20 compounds were active and an MTT assay was performed on MCF-7 and MDA-MB-231 cells. The mechanism underlying the cell growth suppression of compounds **2a** and **2d** was studied further.

Materials and methods
=====================

Virtual screening
-----------------

ERβ pharmacophore was used to screen Maybridge and Enamine databases using Discovery Studio 2.1 in the first round^[@bib16]^. The top 5000 ranked compounds were subjected to the following structure-based screening. The crystal structure (PDB 1X78) was prepared using the Protein Preparation Wizard in the Schrödinger software package and was then used to filter compounds with standard precision in the second round. Next, MM-GBSA was adopted to estimate binding affinity^[@bib17]^. Through visual analysis, 95 compounds were finally selected for purchase from vendors for use in bioassays.

Yeast two-hybrid assay
----------------------

Yeast transformation and the α-galactosidase activity assay were carried out as previously described to evaluate the activity and selectivity of the compounds. Briefly, the yeast strain AH109 was co-transformed with pGADT7-SRC1 (aa 613-773) and pGBKT7-ER LBD (aa 301-553 of ERα and 248-510 of ERβ). In agonist assays, the yeast transformants were incubated with the tested compounds for 24 h, and in antagonist assays, 1 nmol/L E2 should be added. The α-galactosidase activity was determined by the method of the Clontech manual.

Cell transfection and luciferase reporter assay
-----------------------------------------------

CHO-K1 cells were cultured in phenol red-free DMEM/F12 supplemented with 10% charcoal-stripped FBS at 37 °C in an atmosphere of 5% CO~2~. Then, cells were plated in 24-well plates at 1 d before transfection. Subsequently, cells were cotransfected with the reporter construct pGL2-ERE3-luc and ER expression plasmids pRST7-ERα or pCMV5-ERβ using lipofectamine 2000 (Invitrogen) according to the manufacturer\'s recommendations. The pRL-SV40 renilla luciferase plasmid was also transfected into cells, which served as an internal control for normalizing the results. After 5 h, the transfection medium was replaced with fresh medium containing different concentrations of compounds and the cells were incubated for an additional 24 h. Dual-luciferase assays were performed using the Dual-Luciferase Reporter Assay System (Promega) to measure the luciferase activity according to the manufacturer\'s instructions. All transfections were performed in triplicate.

MTT assay
---------

The MTT assay was performed to measure cell viability and proliferation. Briefly, the MCF-7 and MDA-MB-231 cells were seeded in 96-well plates with phenol red-free DMEM/F12 supplemented with 10% charcoal-stripped FBS at the density of 10^5^ cells/mL. The cells were incubated with the tested compounds with a series of concentrations (0.01, 0.1, 1.0, 10, 25, 50, and 100 μmol/L) at 37 °C in a humidified atmosphere with 5% CO~2~ for 48 h. Then, the cells in each well were treated with 20 μL of 5 mg/mL MTT and maintained for another 4 h. Absorbance at 570 nm was determined with a Synergy 2 multimode microplate reader (BioTek) after the formazan crystals were dissolved with 150 μL of DMSO.

Cell cycle analysis
-------------------

MDA-MB-231 cells were seeded into 6-well plates at a density of 2×10^5^ per well and treated with various concentrations of **2a** or **2d** for 48 h. Cells were harvested, washed twice with cold PBS, and fixed in 70% ethanol at 4 °C overnight. Then, the pellets were rinsed in PBS and resuspended in 1 mL PBS containing 50 μg RNase for 30 min at 37 °C before addition of propidium iodide (50 μg/mL) for DNA staining in the dark at 4 °C for 30 min. Cell cycle distribution in G~0~/G~1~, S, and G~2~/M phase was analyzed using the BD FACSCalibur flow cytometer and ModFit software (Verity Software House Inc, Topsham, ME, USA).

Western blot
------------

MDA-MB-231 cells were cultured with DMEM/F12 supplemented with 10% charcoal-stripped FBS and seeded into 6-well plates at a density of 2×10^5^ cells/well. Then, cells were treated with 1 nmol/L E2 and different concentrations of **2a** or **2d** for 48 h. After that, the cells were washed twice with ice-cold PBS and lysed in lysis buffer (20 mmol/L Tris, pH 7.5, 150 mmol/L NaCl, 1% Triton X-100) containing protease and phosphatase inhibitors for 30 min on ice. After centrifugation at 10 000*×g* at 4 °C for 10 min, equal amounts (60 μg) of cell lysates (supernatant) were separated by 12% SDS-PAGE and transferred to PVDF membrane (Millipore). Then, the membrane was blocked in 5% non-fat milk in TBST buffer for 1 h, and incubated with anti-cyclin A, anti-cyclin E and anti-cdk2 antibodies (Bioworld) at 4 °C overnight, followed by horseradish peroxidase-conjugated secondary antibodies. Bound antibodies were measured and quantified using an enhanced chemiluminescence (ECL) system (Amersham Pharmacia Biotech, Piscataway, NJ, USA).

Results
=======

Virtual screening
-----------------

1 856 391 compounds from the Maybridge and Enamine databases were filtered by ERβ pharmacophore, which contained four features: one aromatic ring, one hydrogen bond donor and two hydrophobes. According to the fitness, the top 5000 ranked compounds were stored for the next docking-based screening with ERβ crystal structure (PDB 1X78). Docking score and Molecular Mechanics-Generalized Born Surface Area (MM-GBSA) were adopted in this process. Additionally, we visually analyzed the compound binding poses by forming one or more H-bonds with Glu305 or Arg346 plus an edge-to-face π--π interaction with Phe356. Finally 95 compounds were selected and purchased for bioassay.

*In vitro* agonistic and antagonistic activity
----------------------------------------------

It has been previously demonstrated that a yeast two-hybrid (Y2H) system, through the combination of the human ERα or ERβ and co-activator SRC1 in the AH109 yeast strain, could be used as a rapid, sensitive and reproducible method to detect novel ER ligands. Among the 95 compounds, 20 ([Figure 2](#fig2){ref-type="fig"}) were confirmed to be active to ERα or ERβ in the Y2H system. [Table 1](#tbl1){ref-type="table"} shows the activities of these bioactive compounds and their effects on the biological behaviors of breast cancer cells. In these ligands, 10 compounds showed agonistic activity, and 8 had antagonistic activity. Compounds **3a** and **3b** were indicated as partial agonists of ERα. The majority of the compounds had potent activities for both subtypes, with EC~50~ or IC~50~ values below 10 μmol/L. Of the agonists, 9 compounds (**1a--1h, 1j**) had selective activity for ERβ, and 6 compounds (**1a--1f**) showed absolute ERβ selectivity. EC~50~ values of the most potent agonist (**1i**) were 0.130 and 0.0647 μmol/L for ERβ and ERα, respectively. To determine the agonistic effectiveness of these compounds, we also evaluated the 10% relative effective concentration (REC~10~), which is the concentration of the tested compound that shows 10% agonistic activity of 17β-estrodial (E2). The REC~10~ values were interrelated with EC~50~ for most compounds. As for antagonists, although they mostly had equal activity to both subtypes in Y2H assay, some of them exhibited selective anti-proliferative against ERβ-positive MDA-MB-231 such as **2b** and **2e** ([Table 1](#tbl1){ref-type="table"}).

Transcriptional activity
------------------------

To estimate the impacts of some agonists and antagonists which had better activities in the Y2H assay on biological systems, we investigated the transcriptional activity of **1g**, **1h** (agonists) and **2a**, **2d** (antagonists) using a transactivation assay. Due to a high degree of transfectability, CHO-K1 cells were used for the luciferase reporter assay experiment as described in the Methods. CHO-K1 cells were cotransfected with expression plasmids encoding either ERα or ERβ, where the luciferase reporter plasmid is driven by ERE, together with a renilla luciferase control plasmid pRL-SV40. Then, cells were treated with different concentrations of compounds. The results of transcriptional activation or repression are shown in [Figure 3](#fig3){ref-type="fig"}. As expected, **1g** and **1h** exhibited a dose-responsive increase in ER transcriptional activity. These agonists had agonistic activity on both ERα and ERβ, and resulted in higher ERE reporter activity at high concentration in comparison to E2 ([Figure 3A](#fig3){ref-type="fig"} and [3B](#fig3){ref-type="fig"}). For antagonists, **2a** and **2d** could inhibit the reporter gene transcription in a dose-dependent manner and block the luciferase induction back to control levels at maximum concentration ([Figure 3C](#fig3){ref-type="fig"} and [3D](#fig3){ref-type="fig"}).

Anti-proliferative activity and the mechanism of action
-------------------------------------------------------

Previous studies indicated that the inhibition of the ER may have anti-tumoral potential against different cancers. Based on the results of the Y2H and luciferase assays, it was predicted that ER antagonists would inhibit proliferation of breast cancer cells. The effects of the compounds on cell proliferation and viability were evaluated using the MTT assays against two breast cancer cell lines, MCF-7 and MDA-MB-231. Cells were treated for 48 h with increasing doses of compounds and then cell proliferation was measured by the MTT method. As expected, ERα-positive MCF-7 cells showed inhibited growth by three compounds, and 70%--90% inhibitory ratios were detected ([Table 1](#tbl1){ref-type="table"}). Meanwhile, exposure to these antagonists except **3b**, which only had antagonism to ERα, also limited proliferation of the MDA-MB-231 cell line. A stronger anti-estrogen response occurred in this cell line, where robust growth inhibition was greater than 98%. Only in MDA-MB-231 cells, but not in MCF-7 cells, did treatment with compounds **2b**, **2e**, and **3a** significantly reduce the cell viability. These data suggested that these antagonists showed higher antagonistic activity for ERβ by contrast with ERα. Thus, MDA-MB-231 cells were chosen for the following studies.

To further investigate the mechanism underlying the cell growth suppression caused by compounds **2a** and **2d**, which showed relatively higher antiproliferative potencies on breast cancer cells, flow cytometry was carried out to analyze the cell cycle distribution after treatment of MDA-MB-231 cells with 50 μmol/L **2a** or **2d** for 48 h. The cells treated with compounds were collected and fixed in 70% ethanol in 4 °C overnight followed by staining with propidium iodide. Then, the DNA content was determined through FACS analysis. As shown in [Figure 4](#fig4){ref-type="fig"}, compared to the control cells, treatment of MDA-MB-231 cells with 50 μmol/L **2a** and **2d** resulted in an increase in the population of cells in the S phase (25.83% *vs* 14.21% and 30.52% *vs* 14.21%), which indicated that **2a** and **2d** caused a S phase blockade in MDA-MB-231 cell, and then reduced the cell proliferation.

The cell cycle is regulated by a series of checkpoints involving cyclins and cyclin-dependent kinases (CDKs). It has been reported that S phase progression is directed by the cyclin A/CDK2 complex, and another complex, cyclin E/CDK2 is necessary in the transition from G~1~ to S phase. To further identify whether the ER antagonists **2a** and **2d**, cause S phase arrest, which could alter the expression of S phase-specific cell cycle regulatory proteins, a protein extract was prepared from compound-treated cells for 48 h, and the expression levels of cyclin A, CDK2, and cyclin E were detected by immunoblotting. We observed that E2 increased the expression of these regulators, whereas both **2a** and **2d** treatment dose-dependently decreased the expression levels of cyclin A and CDK2 ([Figure 5](#fig5){ref-type="fig"}). Meanwhile, the downregulation of cyclin E was only caused by **2d**, while **2a** treatment did not cause significant changes in the protein levels of cyclin E. Taken together, these results suggest that the two tested ER antagonists could attenuate E2 induction, and subsequently induce S phase cell cycle arrest through the down-regulation of cyclin A, CDK2, and cyclin E in MDA-MB-231 cells.

Discussion
==========

Currently, virtual screening is no longer confined to individual application of structure- or ligand-based methods. A combined strategy is proposed to take full advantage of available chemical and biological information, which can reduce the weakness and enhance the strengths of the individual method^[@bib18]^. We designed a good virtual screening protocol that saved computational resources as well as time ([Figure 1](#fig1){ref-type="fig"}). In this protocol, ligand-based pharmacophore filtering that considered the features essential for selective ERβ ligands binding, and structure-based molecular docking that focused the shape and interaction fitness between compounds and ERβ, complemented each other. As we expected, the results of the bioassays indicated that these compounds were mostly ERβ selective, which demonstrated our protocol to be effective.

Similar to known ER ligands, most of the active compounds discovered in our work contained a hydroxyl group. As shown in [Figure 6E](#fig6){ref-type="fig"}, the hydroxyl group of compound **1a** was fitted onto the hydrogen bond donor feature (HD feature) of the ERβ pharmacophore, which was essential for ERβ activity. The other three features, including two hydrophobes and one aromatic ring, were also well matched by a phenolic ring, chlorine atom and fluorobenzene, respectively. The docking pose of **1a** demonstrated that the phenolic part occupied the hydrophobic pocket (S1 subset) of ERβ. The S1 subset was composed of residues Leu301, Ala302, Glu305, Met336, Leu339, Met340, Leu343, Arg346, Phe356, and Leu380 ([Figure 6E](#fig6){ref-type="fig"}). The hydroxyl group of **1a** formed hydrogen bonds with Arg346 and Glu305. This hydrogen bond network was a classical interaction between estrogen receptor and ligands. Meanwhile an "edge to face" π--π interaction was observed between Phe356 and the phenolic part of this molecule, which was also critical for bioactivity^[@bib12],[@bib17],[@bib18]^. In addition, the fluorobenzene part was located in the S2 subset, toward His475. Similar binding modes could also be found for other ligands.

Most of the selective agonists contained a hydrophobic group extended into the S2 subset, such as a fluorobenzene or metoxybenzene. The S2 subset around the His475 of ERβ seemed to accommodate a hydrophobic group. Comparison of **1a** with **1d** revealed that the activity would increase when a chlorine atom was introduced into the phenol part. This result agreed with the conclusion that the introduction of polar groups on the phenol part could enhance the ERβ selectivity from our previous studies^[@bib19],[@bib20]^. A similar phenomenon was also found in other ERβ selective ligands^[@bib21]^.

Most of the antagonists had potent activity for both ER subtypes. A pharmacophore mapping of compound **2a** showed that one hydrophobe feature was not matched, which might be the cause of reduced selectivity for ERβ ([Figure 6D](#fig6){ref-type="fig"}). [Figure 6F](#fig6){ref-type="fig"} shows that **2a** adopted a similar binding mode to **1a**. The phenolic part of **2a** fitted well in the S1 subset and participated in the π-π interaction. A hydrogen bond network was formed with the phenolic hydroxyl group. Such interactions were also found in other antagonists. Moreover, two side chains of **2a** occupied the S2 and S3 subsets. It is reported that the side chain in the S3 subset could affect the conformation of Helix 12 and thus inhibit the function of the ER^[@bib22],[@bib23]^. This indicated that the occupation of the S3 subset was important for ligand behavior and might explain the antagonism of **2a**.

In summary, with the combination of pharmacophore and docking-based virtual screening, 20 compounds were discovered as potent ligands of estrogen receptors. Through the Y2H assay, 10 compounds were determined as agonists and 9 of them showed selective activity for ERβ. A further similarity searching based on these highly selective agonists of ERβ is underway to identify compounds with stronger agonistic activity and higher ERβ selectivity. Moreover, we also found 8 antagonists among the 20 compounds. The ER antagonists exhibited better activity for ERβ, which displayed higher antiproliferative potencies on ERα-negative MDA-MB-231 breast cancer cells than ERα-positive MCF-7 cells. We chose two antagonists, **2a** and **2d**, which exhibited high antagonistic activity in the Y2H assay and high antiproliferative activity, and these compounds were used to further explore the molecular mechanism underlying cell growth suppression. Flow cytometry and Western blot were used to analyze the cell cycle distribution and the expression levels of cell cycle regulatory proteins. Our results indicated that **2a** and **2d** could impair E2 induction, arrest MDA-MB-231 cells in the S phase, and down-regulate the expression of cyclin A, CDK2, and cyclin E, which are S phase-specific cell cycle regulatory proteins, which would subsequently repress cell proliferation. These active compounds reveal that the strategy combining pharmacophore and molecular docking was efficient in the discovery of selective leads, which could be used as potential molecular probes to explore the differences between the two subtypes of estrogen receptors.
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![Scheme of the strategy combining pharmacophore and struture-based virtual screening in this study.](aps201469f1){#fig1}

![Structures of ER ligands discovered in this study.](aps201469f2){#fig2}

![Effects of ER ligands on ERE-luciferase activity in CHO-K1 cells. Two agonists 1g (A) and 1h (B) and two antagonist 2a (C) and 2d (D) were selected to evaluate the ERE-luciferase activity in CHO-K1 cells The transcriptional activation or repression of compounds was assessed using Dual-Luciferase assays. CHO-K1 cells were transfected with expression vectors for ERα or ERβ and an ERE-driven reporter plasmid, and a Renilla luciferase expression plasmid (as transfection control). Cells were treated with compounds at the concentrations indicated. The results were expressed as the ratio of the ﬁreﬂy luciferase activity to the Renilla luciferase activity, and the luciferase activity was relative to that of the control cells treated with DMSO which was set as 1.0. Results were expressed as the mean±SD of three independent experiments.](aps201469f3){#fig3}

![Effects of 2a and 2d on cell cycle distributions of MDA-MB-231 breast cancer cells. MDA-MB-231 cells were exposed to 25 μmol/L (B for compound 2a, D for compound 2d) and 50 μmol/L (C for compound 2a, E for compound 2d) compounds or the vehicle control (DMSO) (A) for 48 h before the cells were harvested, fixed, and stained with propidium iodide, and DNA content was evaluated by ﬂow cytometry. Diagrams of cell cycle distribution (G~1~, S, G~2~) were from one representative of three independent experiments with similar results.](aps201469f4){#fig4}

![Immunoblot analysis for the expression levels of cell cycle regulatory proteins 2a (A) and 2d (B). MDA-MB-231 cells were treated with E2 or compounds at the indicated concentrations. Total cell lysates were prepared and equal amounts of protein (40 μg) were subjected to SDS-PAGE followed by Western blot analysis. The indicated cell cycle regulatory proteins were recognized by antibodies against cyclin A, cyclin E, CDK2. GAPDH was used as an loading control. The Western blots shown here were representative of three independent experiments with similar results.](aps201469f5){#fig5}

![The 2D structures of agonist **1a** (A) and antagonist **2a** (B), **1a** (C), and **2a** (D) mapping onto ERβ pharmacophore model, and the docking poses of **1a** (E) and **2a** (F) with the ligand binding domain (LBD) of ERβ. The pharmacophore is represented in Catalyst form: hydrogen bond donor (HD, violet), hydrophobe (HY, blue), aromatic ring (RA, orange). The LBD consists of three hydrophobic subsets (S1, S2, and S3). Dash lines represent the non-covalent interaction between the ligand and receptor: yellow, hydrogen bonding; red, π--π interaction. For clarity only the names of some critical residues are displayed.](aps201469f6){#fig6}

###### Agonistic or antagonistic activities of the tested compounds and standard compounds on both ER subtypes[a](#tbfnote1){ref-type="fn"}.

  Compd                  ERβ             ERα         Selectivity α/β[c](#tbfnote3){ref-type="fn"}   MCF-7 inhibition (%)[d](#tbfnote4){ref-type="fn"}   MDA-MB-231 inhibition (%)                          
  ------------------ ------------ ----------------- ---------------------------------------------- --------------------------------------------------- --------------------------- -------- ------ ------- -------
  Agonists                                                                                                                                                                                                 
  1a                                  1.41±0.20                         0.620                                                                                                                                  
  1b                                  1.56±0.48                         0.0298                                                                                                                                 
  1c                                  3.49±0.21                         0.320                                                                                                                                  
  1d                                  19.3±0.85                          12.4                                                                                                                                  
  1e                                  1.13±0.61                          1.20                                                                                                                                  
  1f                                  25.5±0.27                         0.600                                                                                                                                  
  1g                                  2.97±0.28                         0.470                                                                                   6.74±0.19            8.17    2.27              
  1h                                 0.910±0.20                         0.200                                                                                   1.85±0.17            1.30    2.03              
  1i                                 0.130±0.19                         0.146                                                                                0.0647±0.00033         0.0450   0.50              
  1j                                 0.630±0.21                           ND                                                                                    2.36±0.18            1.12    3.75              
  Estradiol                        0.00108±0.00007                     0.000183                                                                              0.00105±0.00006        0.0001   0.97              
  Antagonists                                                                                                                                                                                              
  2a                  3.52±0.95                                                                                        4.44±0.070                                                            1.26   69.44   99.03
  2b                   7.29±1.0                                                                                         6.80±0.90                                                            0.93   6.72    98.99
  2c                  7.81±0.28                                                                                         5.84±0.47                                                            0.75   73.84   99.24
  2d                  0.62±0.27                                                                                         0.81±0.96                                                            1.31   89.32   99.80
  2e                  21.7±0.57                                                                                         10.6±0.80                                                            0.49   4.30    94.80
  2f                                                                                                                    2.86±0.16                                                                   66.05    ND
  2g                  0.810±0.33                                                                                       0.810±0.97                                                            1.00   16.89   44.05
  2h                  9.02±0.12                                                                                         7.45±0.41                                                            0.83   25.93   99.2
  Tamoxifen           1.66±0.010                                                                                        2.54±0.12                                                            1.53   93.31   80.45
  Partial agonists                                                                                                                                                                                         
  3a                  5.48±0.75       3.74±0.33                         0.064                                           1.96±0.28                               1.31±0.13            2.03    0.35   5.48    97.98
  3b                                                                                                                    1.19±0.95                               0.33±0.21            0.39           25.31    ND

Data shown are the mean±SD for at least triplicate measurements determined by Y2H assays. This system employs the interaction between human ER LBD and the coactivator SRC 1 (see Experimental section).

10% relatively effective concentration, which is the concentration of the tested chemical showing 10% of agonistic activity of the maximum activity of E2. REC~10~ provides the estrogenic activity relative to that of E2.

Determined by EC~50~ on ERα and ERβ for agonists and by IC~50~ of ERα and ERβ for antagonists.

Relative inhibition rate of anti-proliferative potency determined by MTT assays. The ﬁnal concentration of the compounds is 100 μmol/L, and cells treated with DMSO as control were set to 100% viability. ND: not determined.

[^1]: These authors contributed equally to this work.
